Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.25 SEK | +0.92% | +12.83% | -26.44% |
May. 15 | Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
Sales 2024 * | 154M 14.59M | Sales 2025 * | 189M 17.99M | Capitalization | 2.5B 238M |
---|---|---|---|---|---|
Net income 2024 * | 40M 3.8M | Net income 2025 * | 49M 4.66M | EV / Sales 2024 * | 15.6 x |
Net cash position 2024 * | 108M 10.29M | Net cash position 2025 * | 128M 12.15M | EV / Sales 2025 * | 12.6 x |
P/E ratio 2024 * |
61.8
x | P/E ratio 2025 * |
52.2
x | Employees | 37 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.42% |
1 day | +0.92% | ||
1 week | +12.83% | ||
1 month | +37.34% | ||
3 months | +2.00% | ||
6 months | -20.31% | ||
Current year | -26.44% |
Managers | Title | Age | Since |
---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 01-12-31 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 21-12-31 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 72 | 20-05-04 | |
Director/Board Member | 63 | 18-12-31 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 38.25 | +0.92% | 95,726 |
24-05-30 | 37.9 | +8.13% | 63,492 |
24-05-29 | 35.05 | -.--% | 52,046 |
24-05-28 | 35.05 | -.--% | 73,862 |
24-05-27 | 35.05 | +3.39% | 33,463 |
Delayed Quote Nasdaq Stockholm, May 31, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.44% | 238M | |
-3.43% | 12.45B | |
-3.17% | 8.22B | |
+6.11% | 5.72B | |
+31.98% | 5.67B | |
-10.03% | 4.11B | |
-59.94% | 2.68B | |
+11.23% | 2.68B | |
-5.14% | 2.37B | |
+18.91% | 2.06B |
- Stock Market
- Equities
- GENO Stock